Lymphovascular Invasion as the Major Prognostic Factor in Node-Negative Esophageal Cancer After Primary Esophagectomy

• Published in: Journal of gastrointestinal surgery Vol. 24; no. 7; pp. 1459 - 1468
• Main Authors: Hsu, Chung-Ping, Chuang, Cheng-Yen, Hsu, Po-Kuei, Chien, Ling-I, Lin, Chih-Hung, Yeh, Yi-Chen, Hsu, Han-Shui, Wu, Yu-Chung
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.07.2020; Springer Nature B.V
• Subjects: Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - surgery; Esophageal cancer; Esophageal Neoplasms - pathology; Esophageal Neoplasms - surgery; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagus; Gastroenterology; Gastrointestinal surgery; Humans; Medical prognosis; Medicine; Medicine & Public Health; Neoplasm Invasiveness; Neoplasm Staging; Original Article; Prognosis; Retrospective Studies; Squamous cell carcinoma; Surgery; Survival analysis; Survival Rate; Squamous cell carcinoma; Esophageal cancer; Prognosis
• ISSN: 1091-255X; 1873-4626; 1873-4626
• DOI: 10.1007/s11605-019-04310-0

Background Studies addressing both lymphovascular invasion (LVI) and perineural invasion (PNI) in patients with esophageal squamous cell carcinoma (ESCC) treated with or without neoadjuvant therapy are limited. We aimed to analyze the incidence and prognostic significance of LVI and PNI in patients with thoracic ESCC. Methods This retrospective study included 520 patients with ESCC: 174 patients after neoadjuvant treatment followed by surgery and 346 after primary esophagectomy, from two medical centers. The relationships between LVI, PNI, and other histological factors were evaluated. The Cox regression model was used for survival analysis. Results Positive LVI and PNI were noted in 35.6% and 22.4% of patients with residual primary tumor after neoadjuvant treatment and in 39.6% and 24.0% of patients who underwent primary esophagectomy, respectively. In patients with neoadjuvant treatments, the 5-year overall survival rates were 12.7% and 28.3% in patients with positive LVI and negative LVI, respectively ( p  = 0.001). The 5-year overall survival rates were 6.4% and 29.9% in patients with positive PNI and negative PNI, respectively ( p  < 0.001). In patients who did not receive neoadjuvant treatment, the 5-year overall survival rates were 28.2% and 61.1% in patients with positive LVI and negative LVI, respectively ( p  < 0.001). The 5-year overall survival rates were 30.2% and 52.5% in patients with positive PNI and negative PNI ( p  < 0.001). In subgroup analysis, the presence of PNI was an independent prognostic factor in patients with neoadjuvant treatments, whereas the presence of LVI had more significant prognostic impact in patients with node-negative ESCC after primary esophagectomy. Conclusions Both LVI and PNI statuses are significant prognostic factors for patients with ESCC. However, the prognostic impact of LVI was majorly in the subgroup of node-negative patients who received primary esophagectomy.